Founded in 2018, Lamark Biotech operates in Health Tech offering innovative molecular medicines to support sustainable and affordable healthcare systems globally. The company focuses on developing the...
Funding stage:
Pre-Series A
Last funding:
30/06/2025
Total funding:
$760.22K+
Revenue:
Investors
Employee count:
13
Last 90d
13
Last 90d
Web traffic:
1.08K
1.08K
Last 30d
Last 30d
Lamark Biotech: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders9
Latest Filing Date27 Nov 2025- Funding Events14
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Lamark Biotech
As of 28 November 2025, Lamark Biotech's equity is held by 8 shareholders, with the top three being Vaibhav Bhatia, IAN Capital Fund, and Vellore Institute of Technology- Technology Business Incubator.
Vaibhav Bhatia holds the largest stake in Lamark Biotech at 70.6% as of 28 November 2025.
As of 28 November 2025, founders collectively hold 70.6% equity in Lamark Biotech.
As of 28 November 2025, investors collectively hold 17.9% equity in Lamark Biotech.
Lamark Biotech's ESOP pool stands at 8.2% of total equity as of 28 November 2025.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links